In the ILLUMINATE-C trial, patients with advanced primary hyperoxaluria type 1 and severe renal impairment treated with lumasiran showed decreased plasma oxalate and good safety profiles at 6 months and 12...
The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
The new treatment is the first FDA-approved drug to address the overproduction of cortisol in Cushing disease by blocking the enzyme known as 11-beta-hydroxylase and preventing cortisol synthesis.
The authors of a new study investigated the long-term risk for adulthood end-stage renal disease among individuals who had childhood kidney disease that resolved prior to adolescence.
Patients with end stage renal disease on hemodialysis experience high 30-day unplanned readmissions. Using a large administrative database, researchers investigated reasons for initial admission and...
A study examined the potential of a prognostic tool that could better identify patients with type 1 or type 2 diabetes at risk for end stage renal disease.
A phase 3 trial shows that adding voclosporin to mycophenolate mofetil and low-dose glucocorticoids leads to higher rates of complete renal response and faster reduction in proteinuria for patients with...
Researchers examined the effects of a diet high in potassium on the risk of decline in renal function and cardiovascular disease in patients with type 2 diabetes.
